Skip to content
Trial Eligibility
Menu

The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)

NCT05562167

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

The goals of this project are to determine the effectiveness of acute (2 hours after a single dose) and chronic (after 6 weeks of once-a-day dosing) KNO3 treatment (10mmol) vs. placebo on quadriceps muscle power and on aerobic exercise performance (V̇O2peak) in patients with HFrEF (left ventricular ejection fraction <45%). The investigators hypothesize that both acute and chronic dosing of 10mmol of KNO3 will improve exercise performance in HFrEF. To test this hypothesis, the investors will perform a randomized, double-blind, placebo-controlled, parallel-arm design study.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Heart Failure

Eligibility basics and study details

Study type
Interventional
Phase
Phase 2
Ages
19 to 79 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
Washington University School of Medicine
Last updated on ClinicalTrials.gov
May 6, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Missouri · 1

  • Washington University School of Medicine · St Louis, MO

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.